Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 1,736 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Administration first Clear all

Conditions: PMS
Interventions: escitalopram, placebo; Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 15 Years to 19 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Androgenetic Alopecia (AGA), Androgenetic Alopecia, AGA, Female Androgenetic Alopecia, Hair Loss
Interventions: VDPHL01 QD, Placebo, VDPHL01 BID; Drug
Lead sponsor: Veradermics, Inc.; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 552 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 71
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fort Smith, Arkansas + 65 more

Conditions: Migraine
Interventions: Ubrogepant 100 mg, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 73
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 65 more

Conditions: Melanoma
Interventions: Talimogene Laherparepvec, Pembrolizumab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 713 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 41
States / cities: Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 32 more

Conditions: Type 1 Diabetes, New Onset
Interventions: Anti-thymocyte globulin (ATG), verapamil extended-release capsule, Adalimumab; Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 9 Years to 20 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • New Haven, Connecticut + 8 more

Conditions: Schizophrenia
Interventions: Oxytocin; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Catonsville, Maryland

Conditions: Dysmenorrhea, Chronic Pelvic Pain, Pelvic Pain
Interventions: Naproxen Sodium 550mg, Placebo, Extended Release Acetaminophen (650 mg); Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Carcinoma, Pancreatic Ductal
Interventions: AG-013736, Gemcitabine, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 77
States / cities: Antioch, California • Corona, California • Glendora, California + 57 more

Conditions: Tinnitus
Interventions: Repetitive Transcranial Magnetic Stimulation (rTMS); Device
Lead sponsor: University of Arkansas; Other
Eligibility: 19 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Placenta Accreta
Interventions: Tranexamic Acid (TXA), Sodium Chloride 0.9%; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 64 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Indacaterol 300 μg, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Torrance, California • Lebanon, New Hampshire

Conditions: Kidney Diseases
Interventions: Control, Protein, Protein + Exercise; Dietary Supplement · Behavioral
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 30 Years to 80 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 2
States / cities: Chicago, Illinois • Urbana, Illinois

Conditions: COVID-19, Coronavirus, Coronavirus Infections, SARS-CoV 2
Interventions: Hydroxychloroquine - Daily Dosing, Hydroxychloroquine - Weekly Dosing, Placebo oral tablet, Monitoring Visit - Baseline, Monitoring Visit - Week 4, Monitoring Visit - Week 8, Weekly Assessment; Drug · Other · Diagnostic Test
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 75 Years
Enrollment: 624 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Osteoarthritis Knee Pain
Interventions: Duloxetine (DLX), Placebo (PLA); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 40 Years and older
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 10
States / cities: Montgomery, Alabama • Phoenix, Arizona • Spring Valley, California + 7 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Valsartan 160 mg + nateglinide 60 mg, Valsartan 160 mg + nateglinide placebo, Nateglinide 60 mg + valsartan placebo, Valsartan placebo + nateglinide placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years to 99 Years
Enrollment: 9,306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: Multiple Locations, New Jersey

Conditions: Chronic Migraine
Interventions: Galcanezumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 52
States / cities: Phoenix, Arizona • Encino, California • Fullerton, California + 47 more

Conditions: Depression
Interventions: T3; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 64 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Non-Squamous Non-Small Cell Lung Cancer
Interventions: Placebo, Erlotinib, Second-Line Chemotherapy; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 9
States / cities: Gilroy, California • Washington D.C., District of Columbia • Kansas City, Missouri + 6 more

Conditions: Type 2 Diabetes
Interventions: Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham); Device
Lead sponsor: Fractyl Health Inc.; Industry
Eligibility: 21 Years to 70 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 51
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 39 more

Conditions: ADHD - Attention Deficit Disorder With Hyperactivity, Irritability, Aggression Childhood
Interventions: CNS Stimulant, Placebo, CNS Stimulant open label first phase; Drug · Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 7 Years to 12 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Mild Cognitive Impairment, Alzheimer's Disease
Interventions: Lighting Intervention Therapy, Sham LIT; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 50 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: COVID-19
Interventions: SOC + Intravenous Famotidine, SOC + Placebo; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 5
States / cities: Bay Shore, New York • Manhasset, New York • Mount Kisco, New York + 2 more

Conditions: SARS-CoV-2 Infection
Interventions: BTL-TML-COVID, Placebo; Drug
Lead sponsor: Beech Tree Labs, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Draper, Utah

Conditions: Clostridium Difficile Infection
Interventions: Bezlotoxumab, Placebo, Antibacterial drug treatment (ABD); Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 21
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 18 more

Search by objective public record fields.

Escitalopram for Premenstrual Syndrome (PMS) in Teens: A Pilot Study

Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)

Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants

Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

Brain Blood Flow Changes Elicited by Oxytocin in Volunteers With and Without Schizophrenia

NSAID Use for Treating Dysmenorrhea and Preventing Chronic Pelvic Pain (NSAID HEAL)

Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.

Using PET-CT to Target and Validate Low-frequency TMS as Treatment for Tinnitus

Tranexamic Acid in Adherent Placenta (TAP)

The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Intra Hemodialytic Oral Protein and Exercise (IHOPE)

Will Hydroxychloroquine Impede or Prevent COVID-19

A Study of Duloxetine in Patients With Osteoarthritis Knee Pain

Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications

Evaluation of Galcanezumab in the Prevention of Chronic Migraine

Acceleration and Relapse Prevention With Triiodothyronine (T3) as an Adjunct to Electroconvulsive Therapy (ECT)

A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy

Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes

Predictors of Improvements in Irritability and Aggression in Children With ADHD Treated With CNS Stimulants

7T MRI for Light Therapy in Patients With Mild Cognitive Impairment and Mild AD

Multi-site Adaptive Trials for COVID-19

A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19

Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)